Since December 2018, HansaBioMed Life Sciences is part of , a global leader in the field of exosome based liquid biopsy and precision medicine in cancer.

As part of Exosomics Group, HBM-LS will keep its specific mission,  remaining entirely dedicated to the development of products in the field of exosome sciences and will continue offering to the scientific community its unique and advanced portfolio of products and services for EV research.

is the leading and strategic investor in Exosomics Group.

 

HansaBioMed

Video Gallery